Outset Medical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 21, 2024 at 04:11 pm EST
Share
Outset Medical, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 30.51 million compared to USD 32.01 million a year ago. Net loss was USD 38.6 million compared to USD 41.44 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 0.86 a year ago. Diluted loss per share from continuing operations was USD 0.77 compared to USD 0.86 a year ago.
For the full year, revenue was USD 130.38 million compared to USD 115.38 million a year ago. Net loss was USD 172.8 million compared to USD 162.96 million a year ago. Basic loss per share from continuing operations was USD 3.48 compared to USD 3.38 a year ago. Diluted loss per share from continuing operations was USD 3.48 compared to USD 3.38 a year ago.
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
OUTSET MEDICAL, INC. 
